Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Study shows first empirical evidence of exposure to conflict-of-interest policies

Psychiatrists who are exposed to conflict-of-interest (COI) policies during their residency are less likely to prescribe brand-name antidepressants after graduation than those who trained in residency programs without such policies, according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania.

19 Jan 2013

Fifteen established scientists to receive NARSAD Distinguished Investigator Grants

The Brain & Behavior Research Foundation (formerly NARSAD, the National Alliance for Research on Schizophrenia and Depression) announced the latest recipients of its highly competitive NARSAD Distinguished Investigator Grants.

16 Jan 2013

Cerebrospinal fluid IL-6 increased in schizophrenia

Cerebrospinal fluid levels of interleukin-6 are significantly increased in patients with schizophrenia and major depressive disorder, Japanese study results show.

9 Jan 2013

Fluoxetine stimulates production of new neurons from L1-INP cells

The production of new neurons in the adult normal cortex in response to the antidepressant, fluoxetine, is reported in a study published online this week in Neuropsychopharmacology.

7 Jan 2013

Elevated C-reactive protein linked to psychological distress and depression

Elevated levels of C-reactive protein, a marker of inflammatory disease, appear to be associated with increased risk of psychological distress and depression in the general population of adults in Denmark, according to a report published Online First by Archives of General Psychiatry, a JAMA Network publication.

25 Dec 2012

CBT boosts response in medication-resistant depression

Patients with depression who have not responded to pharmacologic treatment should be offered cognitive behavioral therapy, suggest the results of a randomized trial conducted in a primary care setting.

20 Dec 2012

Naurex announces completion of $38M Series B financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of a $38 million Series B financing led by new investor Baxter Ventures.

17 Dec 2012

Paroxetine could treat vascular complications of diabetes

University of Texas Medical Branch at Galveston researchers have discovered that the commonly used antidepressant drug paroxetine could also become a therapy for the vascular complications of diabetes.

14 Dec 2012

LED light instantly triggers or reverses depression-like behavior in rodents

A specific pattern of neuronal firing in a brain reward circuit instantly rendered mice vulnerable to depression-like behavior induced by acute severe stress, a study supported by the National Institutes of Health has found. When researchers used a high-tech method to mimic the pattern, previously resilient mice instantly succumbed to a depression-like syndrome of social withdrawal and reduced pleasure-seeking - they avoided other animals and lost their sweet tooth.

13 Dec 2012

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

13 Dec 2012

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

Novel antidepressant targets brain receptors responsible for learning and memory

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

7 Dec 2012

CBT may help reduce depression in people who have not responded to antidepressants

For the first time in a large-scale randomised trial, scientists have demonstrated that people with depression who have not responded to treatment with antidepressants are three times more likely to get better if they receive cognitive behavioural therapy (CBT) in addition to antidepressants and usual care.

7 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Antidepressants in normal dosage may positively impact mood and seizure frequency

Epilepsy and depression are common co-morbidities. Concern for the potential of certain antidepressants to induce seizures has led to under-treating depression and anxiety disorders in epilepsy patients. Research presented today at the 66th American Epilepsy Society meeting suggests that antidepressants in normal dosage may have a positive impact on both mood and seizure frequency.

4 Dec 2012

Certain SSRI medications fail to achieve same selectivity for prevention of SUDEP

Scientists from Southern Illinois University today reported the results of a study evaluating the potential effect of two selective serotonin reuptake inhibitors (SSRI) antidepressant medications in reducing the risk of sudden unexpected death in epilepsy (SUDEP).

4 Dec 2012

Suicide ‘a major concern’ in childhood psychosis

Children and adolescents with a first episode of psychosis should be monitored closely for suicidal behavior, say researchers who found that more than 12% of such patients attempted suicide over a 24-month period.

29 Nov 2012

Subthreshold bipolarity common in major depressive disorder

Results from a Polish study show that a substantial proportion of patients with major depressive disorder meet criteria for subthreshold bipolarity.

27 Nov 2012

Holiday healthy eating reminders from Greenwich Hospital

As holiday crunch time fills your schedule, don't give up your exercise. "When times get crazy, the thing people give up is exercise, and that's the key thing a person needs. When a person is excitable from stress, the burst of energy that you get from exercise can help burn the adrenaline off and calm you down," said Erica Christ, RD, CDE, an exercise physiologist at Greenwich Hospital's Weight Loss & Diabetes Center.

22 Nov 2012

Sharp decline in ECT availability and use in the U.S. general hospitals

Electroconvulsive therapy (ECT) is considered the most effective treatment option for patients with severe depression who cannot find symptom relief through antidepressant medications or psychotherapy. In a new study, researchers at Butler Hospital and Bradley Hospital in Rhode Island found a sharp decline in the availability and use of ECT in general hospitals across the U.S.

21 Nov 2012